Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 13/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795848 | 0.91 | ANO1 (0.54) | ANO1MEN1KMT2A | |
| SCHEMBL1796283 | 0.90 | RAB9A (0.47) | MEN1KMT2APOLBRAB9APKM | |
| SCHEMBL1795128 | 0.89 | POLB (0.53) | MEN1KMT2APOLBRAB9APKM | |
| SCHEMBL1798657 | 0.85 | RAB9A (0.48) | ANO1MEN1KMT2APOLBRAB9A | |
| SCHEMBL1796957 | 0.85 | RAB9A (0.47) | ANO1MEN1KMT2APOLBRAB9A | |
| SCHEMBL1796954 | 0.82 | POLB (0.46) | ANO1MEN1KMT2APOLBRAB9A | |
| SCHEMBL1796524 | 0.81 | RAB9A (0.56) | MEN1KMT2APOLBRAB9APKM | |
| SCHEMBL24480003 | 0.81 | KMT2A (0.60) | ANO1MEN1KMT2APOLBRAB9A | |
| SCHEMBL1796451 | 0.81 | ANO1 (0.57) | ANO1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL1795098 | 0.80 | ANO1 (0.64) | ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951806-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | ANO1 754/4885MEN1 582/4885KMT2A 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.